Preparation, structure, cytotoxicity and mechanism of action of ferritin-Pt(II) terpyridine compound nanocomposites. (3rd December 2018)

• Record Type: Journal Article
• Authors: Ferraro, Giarita; Pica, Andrea; Petruk, Ganna; Pane, Francesca; Amoresano, Angela; Cilibrizzi, Agostino; Vilar, Ramon; Monti, Daria Maria; Merlino, Antonello
• Is Part Of: Nanomedicine. Volume 13:Number 23(2018)
• Page Start: 2995
• Page End: 3007
• Publication Date: 2018-12-03
• Subjects: platinum-based drug -- protein metalation -- protein nanocage -- protein–metallodrug interactions -- Pt(II)-terpyridine compounds; Nanotechnology -- Periodicals; Medical technology -- Periodicals; Nanotechnology -- Therapeutic use -- Periodicals; 610.28
• DOI: 10.2217/nnm-2018-0259
• Languages: English
• ISSNs: 1743-5889

Abstract

Aim: A Pt(II)-terpyridine compound, bearing two piperidine substituents at positions 2 and 2′ of the terpyridine ligand (1 ), is highly cytotoxic and shows a mechanism of action distinct from cisplatin.1 has been incorporated within the ferritin nanocage (AFt).Materials & methods: Spectroscopic and crystallographic data of the Pt(II)–AFt nanocomposite have been collected and in vitro anticancer activity has been explored using cancer cells.Results: Pt(II)-containing fragments bind His49, His114 and His132. Pt(II)–AFt nanocomposite is less cytotoxic than1, but it is more toxic than cisplatin at high concentrations. The Pt(II)–AFt nanocomposite triggers necrosis in cancer cells, as free1 does.Conclusion: Pt(II)–AFt nanocomposites are promising vehicles to deliver Pt-based drugs to cancer cells.